Skip to main content
Ishita Drugs & Industries Ltd. logo

Ishita Drugs & Industries Ltd. — Investor Relations & Filings

Ticker · 524400 ISIN · INE806D01016 BSE.NS Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2026-05-30 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 524400

About Ishita Drugs & Industries Ltd.

https://ishitadrugs.com/

Ishita Drugs & Industries Ltd. focuses on the production and distribution of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The company’s product range includes sulpha drugs, specifically Sulfamethoxazole, and nutritional additives such as Folic Acid. It maintains manufacturing operations that prioritize chemical synthesis and high-purity standards to serve a broad client base across global markets. Key activities involve the development of specialized chemical compounds used in various therapeutic formulations. The organization leverages technical expertise in organic chemistry to provide essential components for the healthcare supply chain, emphasizing quality control and process optimization in its manufacturing facilities.

Recent filings

Filing Released Lang Actions
Audited Financial Results for the quarter and year ended 31st March, 2026
Interim / Quarterly Report Classification · 85% confidence The document is a regulatory announcement under SEBI LODR (Reg 30 & 33) of the Board meeting outcomes, which includes the audited standalone financial results for the quarter and year ended March 31, 2026, complete with the Independent Auditor’s Report and detailed line‐item financial statements. It is not a full Annual Report (10‐K) or a simple earnings press release (ER) – it provides substantive financial data for an interim period (quarter) and the year‐end results. As such this aligns with the Interim/Quarterly Report category (IR). FY 2026
2026-05-30 English
Outcome of Board Meeting held on 30th May, 2026
Regulatory Filings Classification · 80% confidence The document is an official letter to the stock exchange (BSE) under SEBI LODR Regulation 30 announcing the outcome of a Board meeting held on May 30, 2026, including approval of audited quarterly and year-end financial results and the auditor’s report. It is not a full Annual Report (10-K), nor merely a report publication notice (RPA). It is a regulatory announcement/filing to satisfy listing obligations, so it best fits the “Regulatory Filings” category (RNS).
2026-05-30 English
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To consider, approve ....
Regulatory Filings Classification · 85% confidence The document is a formal intimation to the stock exchange under SEBI Listing Regulation 29 notifying a forthcoming Board meeting to approve financial results and consider annual report items. It does not itself present financial results (so not an IR or 10-K), nor is it a management change notice (MANG) or proxy/materials for the AGM (PSI). It is a routine regulatory announcement/disclosure filing. Therefore it falls into the general Regulatory Filings category (RNS).
2026-05-23 English
The meeting of the Board of Directors of the Company will be held on Saturday, 30th May, 2026 to transact the following business: 1. To consider and take on records the Audited Financial ....
Regulatory Filings Classification · 93% confidence The document is a notice to the stock exchange under SEBI Listing Obligations (Regulation 29) to inform investors of an upcoming Board meeting to approve audited financial results and related items. It does not present the actual results or financial data itself, nor does it announce management changes; rather, it is a regulatory announcement to schedule a board meeting. This falls under general regulatory filings (RNS).
2026-05-23 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.